Oncoclínicas do Brasil Serviços Médicos S.A. (ONCO3) reported on Tuesday, August 25, 2026, that it received Official Letter No. 196/2026/CVM/SER/GER-1 communicating a decision by the CVM Board that granted appeals and concluded that the tender offer for the acquisition of shares (OPA) provided for in Article 39 of its Bylaws is mandatory.

According to the company, the decision is recorded in a briefing of the Board meeting available on the CVM website, and the regulator reported that the full text of the decision will be published in due course on its webpage. Oncoclínicas stated that it will keep its shareholders and the market informed about any new material development related to the matter.

Invest in global stocks with eToro

Buy shares of Apple, Tesla, Amazon, and other global companies directly on the platform.

Open an eToro account

Commercial partner · Investing involves risk of capital loss · eToro is not regulated as a financial services provider in Brazil, and its services are not supervised by the CVM.

📊 Is ONCO3 worth investing in?

ONCO3Oncoclínicas
15+ years of data
PriceR$ 1.75
Dividend Yield0.00 %
P/LN/A
P/VPA120.70
View full analysis of ONCO3
Tags:
OncoclínicasONCO3